Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024
Adicet Bio, Inc. (ACET)
Last adicet bio, inc. earnings: 5/3 05:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
aceto.com/ir/index.html
Company Research
Source: Business Wire
-Data demonstrate characteristics essential for treatment of autoimmune diseases, including robust tissue homing and complete CD19+ B cell depletion in secondary lymphoid tissue-Results highlight the potential benefits unique to gamma delta 1 CAR T cell therapy and ADI-001's potential as a best-in-class off-the-shelf cell therapy for autoimmune diseases-The company is pursuing ADI-001 in a basket study across six indications including lupus nephritis (LN), systemic lupus erythematosus (SLE), systemic sclerosis (SSc), idiopathic inflammatory myopathy (IIM), stiff person syndrome (SPS) and anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic, gamma delta T cell therapies for autoimmune diseases and cancer, today announced that clinical biomarker data from the ADI-001 Phase 1 GLEAN trial which demonstrates
Show less
Read more
Impact Snapshot
Event Time:
ACET
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACET alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACET alerts
High impacting Adicet Bio, Inc. news events
Weekly update
A roundup of the hottest topics
ACET
News
- Adicet Bio, Inc. (NASDAQ: ACET) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell CarcinomaBusiness Wire
- Adicet Bio, Inc. (NASDAQ: ACET) had its "neutral" rating re-affirmed by analysts at HC Wainwright.MarketBeat
- Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases [Yahoo! Finance]Yahoo! Finance
- Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune DiseasesBusiness Wire
ACET
Earnings
- 8/13/24 - Beat
ACET
Sec Filings
- 11/18/24 - Form 8-K
- 11/15/24 - Form 8-K
- 11/14/24 - Form SC
- ACET's page on the SEC website